Abstract
In recent years new oral anticoagulants have been evaluated in the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, atrial fibrillation to prevent ischemic stroke and in the treatment of acute VTE. While two oral anticoagulants, dabigatran and rivaroxaban, have become available for the prevention of VTE in orthopaedic surgery, other indications still are under evaluation or await approval. There are also areas where these novel drugs have not yet been evaluated. These include patients with acute VTE and cancer, pregnant patients with acute VTE and patient with either rheumatic heart valve disease or artificial heart valves. Finally, in acute care settings, where anticoagulant reversibility is critical, such as during and after coronary artery bypass surgery or acute PCI setting in patients with high bleeding risk, novel intravenous anticoagulant drugs with either short half life or specific antidotes may have added value. This article will focus on these unresolved issues.
Keywords: Thrombosis, new anticoagulants, pregnancy, heart valves, cancer, Anticoagulants, venous thromboembolism, knee arthroplasty, atrial fibrillation, ischemic stroke, dabigatran, rivaroxaban, orthopaedic surgery, rheumatic heart valve disease, artificial heart valves, acute PCI setting, intravenous anticoagulant drugs, coronary artery bypass, tumour, Low-molecular-weight heparin, fondaparinux, hromboprophylaxis, renal dysfunction, creatinine clearance, apixaban, hepatotoxic, hepatic metastases, chemotherapy, Vitamin K antagonists, anti-factor Xa, heparin induced thrombocytopenia, Otamixaban, Eptifibatide in Non-ST, Elevation Acute Coronary Syndrome, myocardial infarction, RB006, antithrombotic prophylaxis, hypercoagulable state
Current Pharmaceutical Design
Title: Further Issues with New Oral Anticoagulants
Volume: 16 Issue: 31
Author(s): M. V. Huisman
Affiliation:
Keywords: Thrombosis, new anticoagulants, pregnancy, heart valves, cancer, Anticoagulants, venous thromboembolism, knee arthroplasty, atrial fibrillation, ischemic stroke, dabigatran, rivaroxaban, orthopaedic surgery, rheumatic heart valve disease, artificial heart valves, acute PCI setting, intravenous anticoagulant drugs, coronary artery bypass, tumour, Low-molecular-weight heparin, fondaparinux, hromboprophylaxis, renal dysfunction, creatinine clearance, apixaban, hepatotoxic, hepatic metastases, chemotherapy, Vitamin K antagonists, anti-factor Xa, heparin induced thrombocytopenia, Otamixaban, Eptifibatide in Non-ST, Elevation Acute Coronary Syndrome, myocardial infarction, RB006, antithrombotic prophylaxis, hypercoagulable state
Abstract: In recent years new oral anticoagulants have been evaluated in the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, atrial fibrillation to prevent ischemic stroke and in the treatment of acute VTE. While two oral anticoagulants, dabigatran and rivaroxaban, have become available for the prevention of VTE in orthopaedic surgery, other indications still are under evaluation or await approval. There are also areas where these novel drugs have not yet been evaluated. These include patients with acute VTE and cancer, pregnant patients with acute VTE and patient with either rheumatic heart valve disease or artificial heart valves. Finally, in acute care settings, where anticoagulant reversibility is critical, such as during and after coronary artery bypass surgery or acute PCI setting in patients with high bleeding risk, novel intravenous anticoagulant drugs with either short half life or specific antidotes may have added value. This article will focus on these unresolved issues.
Export Options
About this article
Cite this article as:
V. Huisman M., Further Issues with New Oral Anticoagulants, Current Pharmaceutical Design 2010; 16 (31) . https://dx.doi.org/10.2174/138161210793563356
DOI https://dx.doi.org/10.2174/138161210793563356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews Resuscitation of the Patient with the Functionally Univentricular Heart
Current Pediatric Reviews Cardiac Regeneration: Stem Cells and Beyond
Current Medicinal Chemistry Chinese Medicine in Inhalation Therapy: A Review of Clinical Application and Formulation Development
Current Pharmaceutical Design Strategies for Integral Metabolism Profile of Multiple Compounds in Herbal Medicines: Pharmacokinetics, Metabolites Characterization and Metabolic Interactions
Current Drug Metabolism Patent Selections:
Recent Patents on Medical Imaging Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Human-derived Biomaterials for Biomedical and Tissue Engineering Applications
Current Pharmaceutical Design Current Pharmacologic Management of Pediatric Heart Failure in Congenital Heart Disease
Current Vascular Pharmacology The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Issues and Progress in Isolation of Susceptibility Genes of Essential Hypertension
Current Hypertension Reviews Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Impact of Magnetic Nanoparticles in Biomedical Applications
Recent Patents on Drug Delivery & Formulation Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Vascular Calcification in Chronic Kidney Disease: Role of Disordered Mineral Metabolism
Current Pharmaceutical Design Mass Spectrometric (MS) Analysis of Proteins and Peptides
Current Protein & Peptide Science Controversies in Anticoagulant Therapy in Vitreo-Retinal Surgery
Current Pharmaceutical Design